Şunu aradınız:: discussion (Danca - Fince)

transcript of the discussion
transcript of the discussion

for the remainder of the period the financial perspectives are currently under discussion .
for the remainder of the period the financial perspectives are currently under discussion .

titel position paper on voting in the framework of the discussion and adoption of cpmp opinions
nimi position paper on voting in the framework of the discussion and adoption of cpmp opinions

points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:
points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:

ved afslutningen er mange balloner fløjet ind i en blue skies discussion for the future og med mindre håndgribelige resultater end håbet.
matkan loppupuolella monet palloista ovat lähteneet lentoon tulevaisuutta koskevassa sinitaivaskeskustelussa( blue skies discussion for the future) ja toivottua vähemmän konkreettisin tuloksin.

discussion paper on possible pre- clinical studies to investigate addiction and dependence/ withdrawal related to use of ssris
dependence/ withdrawal related to use of ssris concept paper on the development of a cpmp points to consider on the need for

adjustment for multiplicity and related topics points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:
adjustment for multiplicity and related topics points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:

choice of non- inferiority margin points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:
choice of non- inferiority margin points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:

needs to be met in the short or long term recent events relating to the revision of budgetary figures and recent discussion conducted at ecofin council and commission levels have shown that there is an urgent need to continue improving the quality of fiscal statistics through enhanced monitoring of the data reported by member states and candidate countries .
needs to be met in the short or long term recent events relating to the revision of budgetary figures and recent discussion conducted at ecofin council and commission levels have shown that there is an urgent need to continue improving the quality of fiscal statistics through enhanced monitoring of the data reported by member states and candidate countries .

63) note for guidance on photosafety testing points to consider document on the need for assessment of reproductive toxicity of human insulin analogues discussion paper on environmental risk assessments of non- gmo containing medicinal products for human use non- clinical documentation of medicinal products with ‘ well- established use ’ note for guidance on the need for non- clinical testing of pharmaceuticals in juvenile animals discussion paper on the non- clinical safety studies to support single low dose clinical screening studies in man note for guidance on specification limits for residues for heavy metal catalysts in medicinal products points to consider on xenogeneic cell therapy note for guidance on comparability of biotechnology products pre- clinical and clinical issues points to consider on the assessment of the potential for qt interval prolongation by non- cardiovascular medicinal products note for guidance on risk assessment of medicinal products on human reproductive and development toxicities: from data to labelling
63) note for guidance on photosafety testing points to consider document on the need for assessment of reproductive toxicity of human insulin analogues discussion paper on environmental risk assessments of non- gmo containing medicinal products for human use non- clinical documentation of medicinal products with ‘ well- established use ’ note for guidance on the need for non- clinical testing of pharmaceuticals in juvenile animals discussion paper on the non- clinical safety studies to support single low dose clinical screening studies in man note for guidance on specification limits for residues for heavy metal catalysts in medicinal products points to consider on xenogeneic cell therapy note for guidance on comparability of biotechnology products pre- clinical and clinical issues points to consider on the assessment of the potential for qt interval prolongation by non- cardiovascular medicinal products note for guidance on risk assessment of medicinal products on human reproductive and development toxicities: from data to labelling